NEW YORK (GenomeWeb News) – Simulations Plus said today that it has signed a multi-year collaboration pact with Hoffmann La Roche, under which the pharmaceutical firm will provide funding and feedback in developing the firm’s GastroPlus software program for drug-drug interaction studies.
Lancaster, Calif.-based Simulations Plus said Roche would provide funding for the equivalent of one full-time scientist for two years.
“This collaboration will accelerate the implementation of what we expect to be the most advanced drug-drug interaction capability in the industry,” Viera Lukacova, Simulation Plus’ product manager for GastroPlus, said in a statement. “We’re especially pleased to have Roche scientists involved in this effort, as they have provided invaluable feedback and guidance to the implementation of our PBPK (physiologically based pharmacokinetics) capability in GastroPlus.”
The firm did not disclose terms of the collaboration.